INTRODUCTION
============

It has now become widely accepted by neuroscientists and the clinical community that mental illness can arise from multiple sources and causes, including genetic mutations or epigenetic effects, and key environmental impacts during early development, and adolescence. A need for an ongoing reappraisal of how best to study and classify mental illness is also acknowledged, including the development of circuit-level frameworks for understanding different modality deficits in depression (e.g., [@B153]; [@B230]), autism spectrum disorders (ASD; e.g., [@B72]; [@B125]; [@B235]; [@B58]), and schizophrenia (e.g., [@B198]; [@B158]; [@B139]; [@B89]).

Similarly, novel structural and molecular targets in brain that might underpin better treatments for the debilitating conditions encompassed by the clinical spectrum of anxiety, major depression, and related psychiatric illnesses need to be identified and explored. In this regard, it is clear that neuromodulatory systems that utilize monoamine and peptide transmitters play a key role in the neurophysiology of circuits associated with affective behavior and cognition ([@B82]; [@B124]; [@B212]), and they can be both aberrant in psychiatric pathology and targets for novel treatments (e.g., [@B54]; [@B82]; [@B107]).

Relaxin-3 is a highly conserved neuropeptide that is abundantly expressed in four small groups of largely γ-aminobutyric acid (GABA) projection neurons in mammalian brain ([@B19]; [@B34]; [@B204]), and is involved in regulating aspects of physiological and behavioral stress responses and the integration of sensory inputs (see [@B194]). Recent reviews have highlighted the putative role of relaxin-3 in the control of feeding and the neuroendocrine axis ([@B203]; [@B65], [@B64]). However, existing neuroanatomical and functional evidence also suggests the GABA/relaxin-3 system acts as a broad "arousal" network which is highly responsive to environmental stimuli (neurogenic stressors) and modulates stress responses and other key behaviors/neural processes. These effects are mediated via a variety of mechanisms, such as influencing hippocampal theta rhythm and associated learning and memory, and via putative actions throughout the limbic system ([@B204]; [@B118], [@B115]; [@B15]). Here, in the broader context of the potential for neuropeptide-receptor systems as therapeutic drug targets ([@B82]), we review existing experimental data on relaxin-3 and modulation of its receptor, relaxin family peptide 3 receptor (RXFP3), in rodents and highlight its relevance to the etiology of various neuropsychiatric disorders.

NEUROPEPTIDE-RECEPTOR SYSTEMS AS TARGETS FOR TREATMENT OF NEUROPSYCHIATRIC DISORDERS
====================================================================================

Since the early discovery of "substance P" ([@B221]), a plethora of neuropeptide-receptor systems have been identified and characterized (see [@B82]). Neuropeptides are commonly co-released with GABA/glutamate and monoamine transmitters, and generally signal through G-protein coupled receptors to modulate a broad range of neural processes and behaviors. The potential attractiveness of neuropeptide-receptor systems as therapeutic drug targets is enhanced by their high level of signaling specificity. For example, expression of neuropeptides is often restricted to small populations of neurons within a small number of brain nuclei (e.g., orexin, MCH, and neuropeptide S; [@B232]; [@B181]; [@B180]), and neuropeptides frequently bind to their receptors with high affinity and specificity due to their generally large allosteric binding sites ([@B82]). Neuropeptides are also often preferentially released under states of high neuronal firing frequency in response to the nervous system being challenged, as can occur during acute or chronic environmental stress and/or in association with neuropsychiatric disorders ([@B77], [@B76]; [@B78]).

These characteristics suggest that therapeutic drugs which target neuropeptide systems may be less prone to unwanted "non-specific" side-effects compared to current drug treatments. For example, although tricyclic antidepressants are relatively effective at increasing 5-hydroxytrypamine (5-HT) and noradrenaline signaling to reduce the symptoms of major depression, they are hampered by cross-reactivity with other transmitter systems and reduce histamine and cholinergic signaling, which contributes to unwanted side effects ([@B227]). Even their "replacement" drugs (selective serotonin reuptake inhibitors, SSRIs) are associated with shortcomings such as slow onset of action and patient resistance, and side effects including sexual dysfunction, and weight gain ([@B153]). Similar problems have been encountered in the development of antipsychotics to treat schizophrenia ([@B206]), suggesting that more selective drugs that target relevant peptide receptors could have broad therapeutic applications ([@B76]; [@B78]; [@B82]).

Interest in the therapeutic potential of neuropeptide-receptor systems has further increased following a number of studies which implicate their dysregulation as contributing to disease susceptibility. For example, narcolepsy is strongly associated with reduced orexin signaling ([@B35]); post-traumatic stress syndrome (PTSD) susceptibility and panic has been linked to pituitary adenylate cyclase-activating polypeptide (PACAP) receptor-1 and corticotrophin-releasing factor (CRF) receptor-2 signaling ([@B171]; [@B102]; see also [@B55]); and neuropeptide Y (NPY) and CRF appear to play a role not only in the underlying pathophysiology of schizophrenia and depression, but as likely downstream mediators of the therapeutic effects following treatment with monoamine-targeting drugs ([@B10]; [@B88]; [@B242]; [@B155]). Not surprisingly, the antidepressant potential of drugs which directly target NPY and CRF signaling is currently under investigation ([@B162]), while drugs that target receptors for neurotrophic factors and other neuropeptides, such as brain-derived neurotrophic factor (BDNF; [@B220]) and neuropeptide S (NPS; [@B164]), offer considerable promise as antidepressants and anxiolytics ([@B185]; [@B131]), in light of the effects of the native peptides in relevant animal models of neurogenesis, and neural structure and activity ([@B174]; [@B169]).

However, from a translational viewpoint, over the last two decades pharmaceutical and biotechnology groups have been attempting to target neuropeptide systems to treat various CNS disorders and despite encouraging pre-clinical data, clinical studies investigating the antidepressant potential of neuropeptide receptor-targeting drugs have yielded mixed findings. For example, the neurokinin 1 (NK~1~) antagonist "aprepitant," which is effective at treating nausea during chemotherapy ([@B52]), was unsuccessful in the treatment of major depression ([@B92]). CRF receptor-1 antagonists are also yet to demonstrate clear antidepressant properties ([@B25]), although anxiolytic effects are promising ([@B13]); and trials of these compounds against alcohol abuse and relapse are being undertaken ([@B241]). NPY agonists were initially observed to inhibit circulating stress hormones during sleep in healthy controls ([@B9]), while subsequent testing in depressed patients failed to confer therapeutic effects ([@B73]). Although frustrating for industry *and* clinical and basic researchers, in regard to depression, these findings are more likely to reflect the complex underlying nature of the targeted disorder and its symptoms, rather than inherent flaws with neuropeptide-receptor systems as drug targets. Indeed, more recently, drugs that target orexin receptors have demonstrated promise in the treatment of sleep disorders ([@B83]; [@B231]).

THE NEUROPEPTIDE RELAXIN-3 AND ITS RECEPTOR, RXFP3
==================================================

Relaxin-3 is a two chain, 51 amino acid neuropeptide discovered by our laboratory in 2001 ([@B19]; [@B34]; [@B173]). Relaxin-3 is the ancestral gene of the relaxin family of peptides ([@B228]), which includes the namesake peptide "relaxin" (H2 relaxin or relaxin-2 in humans) that was observed to relax the pelvic ligament in guinea pigs almost a century ago ([@B75]). In contrast to the many and varied peripheral actions of relaxin ([@B187]; [@B16]), relaxin-3 is abundantly expressed within the mammalian brain ([@B19]; [@B34]) and acts as a neurotransmitter by activating its cognate G-protein coupled receptor, RXFP3 \[also known as GPCR135, SALPR, and GPR100; [@B127]; [@B109]; [@B32]; see [@B18], [@B16]\]. Although research in this area is still in its relative infancy ([@B194]), several key features have highlighted relaxin-3/RXFP3 systems as an attractive putative target for the treatment of cognitive deficits, and neuropsychiatric disorders, including depression.

Neuroanatomical studies conducted in the rat ([@B34]; [@B204]; [@B116]), mouse ([@B195]) and macaque ([@B119],[@B120]) have revealed that relaxin-3 is mainly expressed within neurons of the pontine *nucleus incertus*(NI;[@B67]; [@B161]; [@B179]), while smaller populations are present in the pontine raphé, periaqueductal gray, and a region dorsal to the substantia nigra (see **Figure [1](#F1){ref-type="fig"}**). Relaxin-3 containing neurons in these areas innervate a broad range of target forebrain regions rich in RXFP3. NI relaxin-3 neurons are predominately GABAergic ([@B116]; [@B42]), and it is likely relaxin-3 signaling confers complimentary inhibitory effects to the primary transmitter, as in cell-based studies RXFP3 activation is linked to G~i/o~ and reduces cAMP accumulation ([@B214]). In recent electrophysiological experiments, however, RXFP3 activation was able to hyperpolarize *or*depolarize presumed RXFP3-positive neurons within the rat intergeniculate leaflet ([@B30]), suggesting the effect of receptor activation or inhibition may vary with the neurochemical phenotype and connectivity of the target neuron, as described for other peptides. RXFP3 activation also stimulates ERK1/2 MAP kinase and other pathways *in vitro* ([@B213]), although related changes in gene expression or precise roles of RXFP3 signaling within distinct neuronal populations *in vivo* remain unknown.

![**(A,B)** Low and high magnification micrographs of a coronal section through the mouse NI, displaying neurons positive for relaxin-3-like fluorescent immunoreactivity. The region displayed in **(B)** is outlined in **(A)**. The location of the midline (m/l) is indicated with a dotted line. Anterior-posterior coordinates from bregma, -5.38 mm. Scale bars **A**, 100 μm; **B**, 250 μm. **(C)** Schematic parasagittal representation of the rodent brain, illustrating the ascending relaxin-3 system and the distribution of RXFP3 in regions grouped by function. Amyg, amygdala; Arc, arcuate nucleus; BST, bed nucleus of stria terminalis; Cb, cerebellum; CgC, cingulate cortex; Cx, cerebral cortex; DBB, diagonal band of Broca; DG, dentate gyrus; DMH, dorsomedial nucleus of hypothalamus; DR, dorsal raphé nucleus; dSN, region dorsal to the substantia nigra; DTg, dorsal tegmental nucleus; Hi, hippocampus; Hypo, hypothalamus; IC, inferior colliculus; IGL, intergeniculate leaflet; IPN, interpeduncular nucleus; LH, lateral hypothalamus; LPO, lateral preoptic area; MLF, medial longitudinal fasciculus; MR, median raphé; NI, nucleus incertus; OB, olfactory bulb; PAG, periaqueductal gray; PnR, pontine raphé; PVA, paraventricular thalamic area; PVN, paraventricular hypothalamic nucleus; RSC, retrosplenial cortex; S, septum; SC, super colliculus; SuM, supramammillary nucleus; Thal, thalamus.](fphar-05-00046-g001){#F1}

The distribution of relaxin-3-positive axons and RXFP3 mRNA/binding sites within key midbrain, hypothalamic, limbic, and septohippocampal circuits of the rodent and primate brain ([@B116], [@B119]; [@B195]) suggests relaxin-3/RXFP3 neural networks represent an "arousal" system that modulates behavioral outputs such as feeding and the responses to stress; and associated neuronal processes including spatial and emotional memory and hippocampal theta rhythm (see **Figure [1](#F1){ref-type="fig"}**). These actions have been investigated in a number of functional studies in rodents (see [@B118]; [@B194]; [@B65] for review). As numerous neuropsychiatric disorders are either associated with alterations in these processes and behaviors, and/or can be therapeutically treated by drugs which modulate these processes and behaviors ([@B128]; [@B8]; [@B131]; [@B206]; [@B139]), the relaxin-3/RXFP3 system has considerable potential as a novel therapeutic target and warrants further investigation.

RELAXIN-3/RXFP3 SIGNALING: A NOVEL TARGET FOR THE TREATMENT OF DEPRESSION?
==========================================================================

IS RELAXIN-3 IS AN "AROUSAL" TRANSMITTER?
-----------------------------------------

Wakefulness, along with highly aroused behavioral states such as when an animal is alert, attentive, active, or engaged in exploratory behavior, are mediated by the interactive signaling of a range of "arousal" neurotransmitters ([@B183]). Several arousal transmitters and their associated neural networks and single or multiple target receptors have been identified, including the monoamines 5-HT, acetylcholine, noradrenaline, and dopamine ([@B153]; [@B183]; [@B22]), and the peptides orexin, melanin-concentrating hormone (MCH) NPY, CRF, and NPS ([@B76]; [@B232]; [@B88]; [@B181]; [@B237]; [@B27]). Indeed, it is now widely thought, based particularly on studies using optogenetic control of neural pathways, that selective spatiotemporal recruitment and coordinated activity of various cell type-specific brain circuits may underlie the neural integration of reward, learning, arousal, and feeding.

As mentioned, considerable neuroanatomical evidence suggests relaxin-3 should be thought of as an arousal neurotransmitter. For example, relaxin-3 neurons project to several areas that regulate arousal, such as the midbrain, cortex, thalamus, and limbic and septohippocampal regions, in a similar way as the monoamine and other peptide arousal systems ([@B116]; [@B195], [@B194]). In fact, the "restricted" localization of relaxin-3 (GABA) neurons and the broadly distributed relaxin-3 projections throughout the brain are remarkably similar to those of the raphé/5-HT ([@B199]; [@B143]; [@B104]) and locus coeruleus/noradrenaline ([@B90]; [@B202]; [@B22]) pathways/networks.

Arousal neurotransmitter systems are extensively interconnected, and relaxin-3 fibers, and RXFP3 are enriched within the pedunculopontine/laterodorsal tegmentum and basal forebrain, periaqueductal gray and lateral hypothalamus; which contain interconnected populations of neurons which produce acetylcholine, dopamine and orexin/MCH, respectively ([@B183]). Furthermore, along with 5-HT and orexin fibers and receptors ([@B138]; [@B123]; [@B168]; [@B208]; [@B166]), relaxin-3 fibers/RXFP3 are enriched within the sensory and photic integrative thalamic center, known as the intergeniculate leaflet ([@B69]; [@B145]), and application of an RXFP3 agonist can excite (depolarize) NPY neurons within this region ([@B30]), which project to the suprachiasmatic nucleus and promote wakefulness ([@B188]; [@B208]; [@B237]). Furthermore, rat NI relaxin-3 neurons express the 5-HT~1A~ receptor (and possibly other 5-HT receptors), and chronic 5-HT depletion increased relaxin-3 mRNA in the NI ([@B140]); while in preliminary electrophysiological studies, bath application of orexin activated rat NI relaxin-3 neurons in a brain slice preparation ([@B31]).

Indeed, arousal and stress transmitter systems, including CRF and orexin peptides and their receptors, have long been implicated in reward and drug seeking behavior ([@B98]; [@B93]) and we recently demonstrated that antagonism of RXFP3 in brain -- specifically within the bed nucleus of the stria terminalis -- reduced self-administration of alcohol and cue- and stress (yohimbine)-induced relapse in alcohol-preferring iP rats ([@B178]). As monoamines ([@B157]; [@B22]) and peptides ([@B152]; [@B33]; [@B131]) are established or putative targets for the development of antidepressant drugs ([@B230]), the status of relaxin-3/RXFP3 as a similar and likely interconnected arousal system suggests a similar therapeutic potential.

Abnormal sleep and the disruption of circadian rhythm are common symptoms of the major neurodegenerative diseases ([@B70]) and neurological disorders such as depression ([@B21]), schizophrenia ([@B211]), and anxiety ([@B144]), and the success of current pharmacological treatments for these diseases appears to be mediated in part through normalizing these symptoms ([@B129]). In line with neuroanatomical features, a number of functional studies suggest that relaxin-3 signaling promotes wakefulness. In rats, relaxin-3 mRNA displays a circadian pattern of expression which peaks during the dark/active phase ([@B14]), and intracerebroventricular (icv) infusion of an RXFP3 agonist during the light/inactive phase has been reported to increase locomotor activity ([@B201]). These data were partly replicated in mice, in which chronic virally mediated delivery of an RXFP3 agonist into the cerebroventricular system slowed the decline in locomotor activity associated with habituation to a novel environment ([@B190]). Mixed background (129S5:B6) relaxin-3 knockout (KO) mice were also hypoactive compared to wildtype littermate controls when placed in novel environments ([@B193]), and although this phenotype was not reproduced in C57BL/6J backcrossed colonies; during the dark/active phase backcrossed relaxin-3 KO mice traveled less distance on voluntary home-cage running wheels and appeared to spend more time sleeping than wildtype controls ([@B192]). These data are consistent with a possible regulation of circadian activity by relaxin-3/RXFP3 signaling in the IGL and network-induced changes in SCN activity ([@B30]), a possibility that is currently being explored in both wildtype and gene deletion mouse strains ([@B80]).

RELAXIN-3 NEURONS ARE INVOLVED IN THE RESPONSE TO STRESS
--------------------------------------------------------

A current view of the stress response is the behavioral and physiological changes generated in the face of, or in anticipation of, a perceived threat. The stress response involves activation of the sympathetic nervous system and recruitment of the hypothalamic-pituitary-adrenal (HPA) axis. When an animal encounters a social, physical or other stressor, these endogenous systems are stimulated and generate a "fight-or-flight" response to manage the "stressful" situation. Acutely, these changes are considered advantageous, but when an organism is subjected to prolonged or chronic stressors, the continuous irregularity in homeostasis is considered detrimental and leads to metabolic and behavioral disturbances ([@B130]). Chronic stress is a well-known trigger for depression in humans, which often involves prolonged over-activation of the HPA axis, resulting in increased circulating glucocorticoids ([@B128]; [@B130]). Since its discovery in 1982 by the late Wylie Vale and others ([@B28]), CRF has been shown to play a key role in the stress response *and* in major depression ([@B152]; [@B10]; [@B162]). A major source of CRF expression is the parvocellular neurons of the paraventricular hypothalamic nucleus (PVN) that project to the portal circulatory system. In response to stress, CRF is released which triggers the HPA axis by stimulating the release of adrenocorticotropic hormone (ACTH) by the pituitary gland. ACTH binds to receptors in the adrenal gland, which responds by secreting cortisol (corticosterone in rodents). CRF is also expressed within a number of other brain regions including the extended amygdala and the raphé nuclei ([@B50]; [@B147]) and produces a range of extra-pituitary effects via CRF~1~ and CRF~2~ receptors that are broadly expressed throughout the brain ([@B44]; [@B216]).

Relaxin-3 neurons within the rat NI express high levels of CRF~1~ receptor ([@B29]; [@B204]; [@B115]), and the majority of these neurons are activated (i.e., display increased relaxin-3 mRNA, Fos immunoreactivity and/or depolarization) following a restraint stress or icv injection of CRF ([@B204]; [@B103]; [@B115]). Relaxin-3 expression in the NI was also increased following a repeated swim stress, and this effect was blocked via pre-administration of the CRF~1~ antagonist, antalarmin ([@B15]). NI neurons are also activated by a range of other stressors, including foot shock, treadmill running, and food deprivation ([@B179]), although their impact on relaxin-3 expression has not been assessed. Similarly, the responsiveness of the other relaxin-3 neuron populations has not yet been investigated. The stress-responsiveness of relaxin-3 neurons appears highly conserved, as gene microarray analysis of three-spine stickleback fish revealed that exposure to a predator markedly increased relaxin-3 expression in the brain compared to controls ([@B182]).

Although the precise location and identity of the CRF neurons that innervate relaxin-3 neurons is unknown, the NI receives strong afferent inputs from the CRF-rich lateral and medial preoptic area ([@B103]; [@B115]), while the close proximity of the NI to the fourth ventricle suggests that volume transfer is also possible ([@B29]). Current data ([@B103]; [@B115]) and the plasticity of CRF *and* CRF receptor expression (see [@B51]) suggest the level of CRF innervation and activation of the NI/(relaxin-3) cells may be altered under different physiological and pathological conditions, along with other aspects of their overall phenotype.

In addition to responding to stress, relaxin-3/RXFP3 signaling is able to modulate a variety of stress-related responses. In a recent report, C57B/6J backcrossed relaxin-3 KO mice were reported to display a "subtle decrease" in anxiety-like behavior compared to WT controls ([@B225]), although a similar phenotype was not observed in a largely parallel study ([@B192]). In a more relevant set of experiments which highlight the anti-depressant potential of relaxin-3/RXFP3 signaling, icv infusion of a specific RXFP3 agonist reduced anxiety- and depressive-like behavior in rats ([@B177]). These findings have been partly corroborated by an independent study, which observed similar reductions in anxiety-like behavior following icv infusion of relaxin-3 in rats ([@B150]). These pharmacological effects might be mediated, at least in part, by actions in the amygdala, which is largely responsible for conferring anxiety-related symptoms that are commonly experienced during depression ([@B79]). The central and medial amygdala displays some of the highest densities of RXFP3 expression within the rodent brain ([@B116]; [@B195]), and injection of a specific RXFP3 agonist into the central amygdala reduced the characteristic freezing fear response displayed by rats when anticipating a foot shock following conventional auditory fear conditioning ([@B117]).

Relaxin family peptide 3 receptor expression is also highly enriched within the PVN ([@B116]; [@B195]), and icv injection of relaxin-3 in rats increased CRF and c-*fos* mRNA within the PVN and increased plasma ACTH, indicative of HPA axis activation ([@B224]). These findings suggest that although the net sum of behavioral responses following "global" (or intra-amygdala) RXFP3 activation appears to be anxiolytic/antidepressant in nature ([@B150]; [@B177]), RXFP3 signaling can in fact either promote or attenuate different aspects of the stress response, depending on the brain region modulated. This feature is shared with several other neuropeptides. For example, rodent studies have demonstrated that orexin and galanin signaling can either increase or decrease anxiety-like behavior, depending on the brain region(s) targeted ([@B24]; [@B142]; [@B114]), while icv administration of NPS has been shown to decrease anxiety while increasing HPA axis activity ([@B232]; [@B196]). NPY (possibly from the arcuate nucleus) can activate the HPA axis via NPY Y1 receptors expressed on PVN CRF neurons ([@B5]; [@B53]); but icv administration of NPY and a specific Y1 agonist inhibits fear behavior during contextual fear conditioning ([@B101]).

High densities of relaxin-3-positive fibers and RXFP3 mRNA/binding sites are also present within several other brain structures that contribute to the central stress response and have been implicated in the etiology of anxiety and depression ([@B116]; [@B195]), including the:(i) *dorsal raphé*, which contains stress-responsive 5-HT neurons that are critical for determining depression susceptibility and recovery ([@B239]; [@B43]); (ii) *hippocampus*, which expresses high densities of glucocorticoid receptors and often displays reduced volume and neurogenesis and impaired function in depressed patients ([@B122]; [@B219]; [@B230]); (iii) *periaqueductal* *gray*, which is involved in fear behavior and associated autonomic responses ([@B218]), and which contains relaxin-3 neurons positive for CRF~1/2~ immunoreactivity ([@B30]); (iv) *bed nucleus of the stria terminalis*, which constitutes a stress integration center that contains CRF-expressing and other peptide containing GABA/glutamate neurons, which strongly influence the PVN and are reportedly dysfunctional in several psychiatric disorders, including depression, anxiety-disorders, and addiction ([@B56]; [@B222]; [@B98]; [@B102]; [@B49]; [@B240]); (v) *medial preoptic area*, in which neurons also express high levels of CRF and strongly project to and influence the PVN ([@B126]; [@B103]); (vi) *lateral habenula*, a key structure mediating the response to emotionally negative states ([@B230]), in which neuron activity was shown recently to be regulated by levels of β-CaMK II expression and to be sufficient to either induce or alleviate depressive-like symptoms in rodents, depending on whether these neurons were activated or inhibited, respectively ([@B105]); (vii) *anterior cingulate cortex*, which acts to stabilize emotional responses via inhibitory projections to the amygdala that are often reduced in depressed patients ([@B8]; [@B230]) and; (viii) *medial prefrontal cortex*, which is dysfunctional in depressed patients and strongly projects to the PVN and amygdala to suppress behavioral responses to stress ([@B57]). The medial prefrontal cortex is of additional interest, as it forms a main source of afferent input into the NI ([@B67]). A recent study has also demonstrated that stimulation of CRF~1~ positive NI neurons that project to the medial prefrontal cortex (either electrophysiologically or via administration of CRF) act to inhibit this region, while electrical or CRF-mediated stimulation of the whole NI impaired long term potentiation within the hippocampo-prelimbic medial prefrontal cortical pathway ([@B59]).

RELAXIN-3 NEURONS MODULATE HIPPOCAMPAL ACTIVITY
-----------------------------------------------

A key feature of hippocampal function is a state of synchronous neuronal firing at theta rhythm (4--10 Hz in humans), which is required for the hippocampus to mediate its important roles in memory formation and retrieval, spatial navigation, and rapid eye movement (REM) sleep ([@B217]). Hippocampal function is disrupted by elevated circulating glucocorticoids during chronic stress, which can contribute to the cognitive deficits seen in depression ([@B149]; [@B47]). Furthermore, a common hallmark of depression is stress-related increases in REM sleep ([@B94]), which is robustly reduced to normal levels following antidepressant treatment ([@B11]), an effect partly mediated by 5-HT signaling ([@B3]). In light of the critical role that hippocampal theta rhythm plays in normal neurological function and its propensity for disruption in disease states, it is not surprising that almost all currently available anxiolytic and pro-cognitive drugs alter hippocampal theta rhythm ([@B136]). It has in fact been suggested that this feature can be used as an "output" for screening the potential effectiveness of new psychoactive drugs ([@B137]).

The ability of ascending brainstem nuclei such as the *reticularis pontis oralis* (RPO) and median raphé to modulate hippocampal theta rhythm is well established. These functions are mediated not only by projections to the hippocampus, but also via innervation of several "nodes" of the septohippocampal system such as the interpeduncular nucleus (IPN), supramammillary nucleus, posterior hypothalamus, and medial septum ([@B217]). In particular, the medial septum has been termed the hippocampal theta rhythm "pace-maker" and contains populations of cholinergic and GABAergic neurons which provide alternating synchronous excitatory/inhibitory input to reciprocally connected hippocampal neurons ([@B217]; [@B223]; [@B68]). The NI sits adjacent to, and is strongly interconnected with, the RPO, median raphé and IPN, and efferent relaxin-3-positive projections innervate the hippocampus and the major nodes of the septohippocampal pathway ([@B116]; [@B207]; [@B195]; [@B42]), including the medial septum which displays a high density of relaxin-3 immunoreactive fibers and terminals which make synaptic contacts with hippocampal-projecting cholinergic and GABAergic neurons in the rat ([@B160]).

Functional studies have confirmed the regulation of hippocampal theta rhythm by the NI. In anesthetized rats, electrical stimulation of the NI induced hippocampal theta rhythm, whereas electrolytic lesion of the NI blocked the ability of the RPO to generate hippocampal theta rhythm ([@B156]; [@B207]). In conscious rats with electrolytic lesions of the NI, theta-dependent behaviors are impaired such as the acquisition of fear extinction in a contextual auditory conditioned fear paradigm ([@B167]). Simultaneous recording of hippocampal and NI field potentials ([@B41]) and electrophysiological recording of NI neurons ([@B115]) have also revealed that these two structures are "theta-synchronized" and individual neurons display coherent firing. Although it is likely that these actions are primarily conferred by GABA (or to a much lesser extent, glutamate) transmission of these septohippocampal-projecting NI neurons ([@B116]; [@B42]), relaxin-3/RXFP3 signaling nonetheless appears capable of contributing to this functional effect. Our laboratory has shown that local infusion of an RXFP3 agonist into the medial septum of anesthetized rats promotes hippocampal theta rhythm, while medial septum infusion of an RXFP3 antagonist in conscious rats inhibits hippocampal theta and theta-dependent spatial memory measured in a spontaneous alternation task ([@B118]).

RELEVANCE OF RELAXIN-3/RXFP3 SIGNALING TO SOCIAL BEHAVIOR AND AUTISM?
=====================================================================

In rodents, social behavior is highly dependent upon three aspects of brain function: (i) *arousal*, which is required for motivation to engage in social contact, and mediates appropriate mood responses ([@B48]); (ii) *stress responses*, which regulate levels of social withdrawal/anxiety ([@B61]) and; (iii) *exploration and social recognition*, which is associated with hippocampal theta rhythm activity ([@B121]). Notably, relaxin-3 has been demonstrated to modulate all of these behavioral aspects.

Abnormal social behavior is associated with depression and is a key symptom of ASD ([@B139]; [@B26]). Human imaging studies indicate that autism is often characterized by structural abnormalities in limbic structures such as the hippocampus ([@B72]; [@B159]), which according to post-mortem studies consists of principal neurons that are smaller in size and are more densely packed ([@B20]). The amygdala is another major limbic structure that has been the focus of many human ([@B215]) and animal ([@B7]) studies of social aggression, and in rodent models of autism, hyperexcitability and enhanced long term potentiation in lateral amygdala neurons has been reported ([@B106]). Reduced activity of the anterior cingulate cortex has been observed in human autistic patients, which is correlated with deficits in attention and executive control ([@B58]). The PVN is another major limbic structure relevant to autism partly due to the presence of oxytocin neurons, which are crucial for mother-infant bonding ([@B141]) and promote social interaction ([@B113]). Autism is associated with loss of PVN oxytocin neurons ([@B135]), and oxytocin is displaying considerable promise in clinical treatment of this disorder ([@B233]). The PVN also contains neurons that express vasopressin, which reciprocally interact with oxytocin neurons and strongly influence social behaviors such as aggression ([@B37]), suggesting similar therapeutic potential ([@B172]; [@B112]).

Relaxin-3/RXFP3 systems are well placed to modulate social behavior and other symptoms of ASD due to their presence throughout the limbic hippocampus, amygdala, anterior cingulate cortex, and PVN. Particularly intriguing, however, is the strong link between relaxin-3 and oxytocin. Oxytocin receptors are expressed within the rat and mouse NI ([@B210]; [@B236]), and microarray/peptidomics analysis revealed that the most striking neurochemical change that occurred within the rat hypothalamus following acute icv infusion of relaxin-3 and resultant activation of RXFP3 (and RXFP1) was a large (\>10-fold) upregulation of oxytocin ([@B150]). In contrast, chronic hypothalamic RXFP3 signaling resulted in an opposite effect, as viral-mediated hypothalamic delivery of an RXFP3 agonist for 3 months reduced hypothalamic oxytocin mRNA by \~50% ([@B63]). Whether some or all oxytocin neurons express RXFP3 or whether these effects are mediated in part or in full by indirect actions, remains to be determined experimentally. Similarly, vasopressin neurons may also be targeted by RXFP3 signaling ([@B63]).

Despite the potential for a role of relaxin-3/RXFP3 signaling in aspects of social behavior, only a single functional study has thus far been reported, which observed that compared to wildtype littermate controls, female 129S5:B6 mixed background relaxin-3 KO mice engaged in fewer encounters with a novel mouse in a social interaction test ([@B193]). Therefore, further studies including those that test the therapeutic potential of RXFP3 agonists in validated rodent models of major ASD symptoms are required. These might also include assessment of aggressive behavior, with the presence of RXFP3 in brain "defensive centers" such as the amygdala, PAG, and ventromedial hypothalamus (see Future Studies of Relaxin-3/RXFP3 System).

RELAXIN-3/RXFP3 CONTROL OF FEEDING AND RELEVANCE FOR EATING DISORDERS?
======================================================================

It is generally accepted that obesity has rapidly reached epidemic proportions, but is also one of the leading preventable causes of death worldwide. Notably, there is evidence that obesity associated metabolic signals markedly increase the odds of developing depression; and depressed mood not only impairs motivation, quality of life and overall functioning, but also further increases the risks of complications associated with obesity ([@B84]). Therefore, curbing the global growth in obesity and associated health problems, and demands on public healthcare, is a major challenge which offers huge economic reward for agencies that develop effective treatments ([@B99]; [@B39]; [@B175]; [@B2]). Conversely, a smaller but important niche exists for the development of orexigenic agents to treat symptoms of decreased appetite and/or cachexia associated with cancer and its treatment, immune deficiency, and anorexia nervosa ([@B197]).

RXFP3 is present in several hypothalamic feeding centers in rat brain ([@B96]) including the PVN ([@B109]), lateral hypothalamus, arcuate, and dorsomedial nuclei ([@B200]; [@B116]). These data prompted a series of pharmacological studies which consistently demonstrated that relaxin-3 and selective RXFP3 agonist peptides are potently orexigenic in rats following acute delivery into the lateral cerebral ventricle ([@B108], [@B110]; [@B133]; [@B201]; [@B186]; [@B81]) or various hypothalamic regions ([@B134]). Chronic delivery of RXFP3 agonists via repeated intra-PVN injection ([@B132]), osmotic minipump (icv) infusion ([@B74]; [@B201]), or viral constructs injected into the PVN ([@B63]) also reliably increase food consumption and bodyweight, and result in metabolic changes such as increased plasma levels of leptin, insulin, and adiponectin, and decreased plasma levels of growth hormone and thyroid stimulating hormone. Co-administration of RXFP3 antagonists are able to prevent the increases in feeding induced by acute RXFP3 agonist injections ([@B100]; [@B71]), but a significant reduction in feeding behavior produced by acute blockade of endogenous relaxin-3/RXFP3 signaling in satiated *and* food restricted rats is yet to be reported; suggesting a graded impact on this heavily regulated homeostatic behavior. Furthermore, relaxin-3 KO mice (C57BL/6J background) do not display any overt differences in feeding or bodyweight under normal housing and dietary conditions ([@B225]; [@B192]), despite an earlier report that mixed (129S5:B6) background relaxin-3 KO mice fed on a diet with higher than normal (moderate) fat content were largely resistant to the obesity observed in WT controls ([@B201]). Clearly this is an important area for further research in normal and other suitable transgenic mice. A recent study suggested that relaxin-3/RXFP3 signaling may be more important under specific physiological conditions, as in stressed female rats with intermittent access to palatable liquid food, relaxin-3 expression in the NI was increased in food restricted versus *ad libitum* fed animals ([@B103]).

Increased feeding is a common side effect of antipsychotic medications ([@B209]), and acute atypical (clozapine) and typical (chlorpromazine and fluphenazine) antipsychotic treatments increased the number of Fos-positive cells in the rat NI ([@B170]). On this basis, it was hypothesized that increased NI activation may be partly responsible for the antipsychotic drug induced increase in feeding behavior, which if correct, would suggest that relaxin-3/RXFP3 signaling might also play a role. Further evidence supporting this theory comes from a gene association study, in which \>400 schizophrenia patients undergoing treatment with antipsychotic medications were assessed, many of whom displayed co-morbid metabolic syndromes ([@B148]). Interestingly, a polymorphism within the RXFP3 gene was significantly associated with obesity, while one polymorphism in the relaxin-3 gene and two in the RXFP3 gene were significantly associated with hypercholesterolemia.

In another gene association study, members of a Puerto Rican family with schizophrenia had a mutation within a chromosome 5p locus, which had earlier been identified in similar studies of familial schizophrenia-like symptoms ([@B23]). This locus contains the RXFP3 gene, and although sequencing of the coding region and proximal promoter did not reveal functionally significant variants, further upstream or downstream promoter regions were not assessed. Antipsychotics block dopamine D2 receptors and are the primary therapy for psychotic, *positive* symptoms (hallucinations/delusions) of schizophrenia ([@B206]; [@B40]). It is possible, however, that modulation of endogenous relaxin-3/RXFP3 signaling might reduce the severity of the *negative* affective symptoms and cognitive deficits displayed in schizophrenic patients. These putative roles might be mediated via actions within limbic structures to modulate relevant neural circuits that regulate theta and other frequency brain oscillations, to enhance attention, working, and episodic memory ([@B118]; [@B139]). However, experimental evidence in support of this speculation is yet to be gathered.

Overall, given the enormity of the obesity epidemic and associated health problems and the lack of understanding of, and effective pharmacological therapies for, eating disorders such as anorexia nervosa, there is a strong justification for further studies that involve chronic manipulation of RXFP3 signaling to assess feeding, metabolism, and body weight.

FUTURE STUDIES OF THE RELAXIN-3/RXFP3 SYSTEM
============================================

Considerable experimental evidence obtained over the last decade suggests that endogenous relaxin-3/RXFP3 signaling promotes arousal and contributes to the central response to stress, and the highly conserved nature of this peptide/receptor system suggests it plays important biological roles. Current data suggest that drugs which act to increase relaxin-3/RXFP3 signaling are likely to have therapeutic/beneficial effects in a range of clinical conditions. Like many other complex neuromodulatory (peptide) systems, however, receptor modulation in different brain regions may confer differential effects; and in a therapeutic context, increased brain RXFP3 activation may produce both beneficial *and* "undesirable" effects. With RXFP3 agonists, in some disorders these may include increased HPA axis activity ([@B224]) and bodyweight gain ([@B133]; [@B65]; [@B103]); while with RXFP3 antagonists these may include decreased arousal and motivation. Therefore, characterizing precise direct and indirect actions of relaxin-3/RXFP3 signaling within the major RXFP3-rich regions of the rodent brain remains an important long term goal. Similarly, neurons in the relaxin-3 rich NI express a large array of receptors for transmitters, and monoamine and peptide modulators ([@B31]; [@B179]; [@B115]), and it will be important to carefully assess how these signals are integrated by the NI relaxin-3 system.

Studies which have centrally administered RXFP3 agonists have mainly employed the icv route, and although it is often assumed that peptides are able to access receptors throughout the whole brain ([@B29]), recent studies in our laboratory using fluorophore-conjugated relaxin family peptides suggest that periventricular regions such as the PVN may be exposed to higher concentrations of peptide ([@B45]). Although RXFP3 agonists or antagonists have been locally infused into the bed nucleus of the stria terminalis ([@B178]), central amygdala ([@B117]), medial septum ([@B118]), and hypothalamic nuclei ([@B134]) of rodents, in connection with actions on reward, fear, spatial memory, and feeding, respectively; many other RXFP3-rich brain regions including those distal to the ventricular system remain to be targeted, including the median raphé, superior and inferior colliculus, intergeniculate leaflet, IPN, supramammillary nucleus, diagonal band of Broca, fields within the dorsal and ventral hippocampus, and the retrosplenial and cingulate cortices (see **Figure [1](#F1){ref-type="fig"}**). Intranasal delivery may be a viable alternate route of peptide administration based on recent studies with insulin, oxytocin/vasopressin and NPS (e.g., [@B87]), but ultimately, characterization of the net effects of activating RXFP3 throughout the brain is required, using highly stable peptides or small synthetic molecules that cross the blood--brain barrier ([@B17]) and can be administered systemically.

In addition to characterizing the function of relaxin-3/RXFP3 at a regional level, it is crucial to characterize the populations of neurons that express RXFP3 within each nucleus/region, and whether they are stimulated or inhibited following RXFP3 activation. Such functional data will provide valuable insights into the mechanisms of relaxin-3 action, but to date, this has only been partially achieved in the intergeniculate leaflet ([@B30]). Based on equivalent studies of similar systems such as the orexins, such features may be complicated, despite the relative simplicity of the one ligand/one receptor, relaxin-3/RXFP3 system.

In the context of arousal, an RXFP3-rich area of particular interest is the lateral hypothalamus ([@B116]; [@B195]). If it is assumed that RXFP3 activation *inhibits* receptor-positive neurons, then it is possible that relaxin-3/RXFP3 may promote arousal by directly inhibiting neurons which express MCH, which act to inhibit arousal ([@B180]). Alternatively, activation of RXFP3 expressed on GABAergic interneurons which project to and inhibit orexin/dynorphin/(neurotensin) neurons in the area ([@B4]; [@B36]; [@B62]), may indirectly disinhibit these neurons, increasing the activity of these arousal-promoting networks. If, however, RXFP3 signaling directly *stimulates* specific target neurons, these scenarios could be reversed. Similar hypothetical circuits can be conceived involving sleep active neurons that express galanin in the ventrolateral preoptic area ([@B66]), 5-HT and non 5-HT neurons in the dorsal and median raphé ([@B146]; [@B95]; [@B97]), and a host of other systems throughout the brain ([@B191]). Traditional immunohistochemical approaches to achieving this goal have been hampered, however, as sufficiently sensitive and specific antisera for RXFP3 are currently unavailable. An alternative approach has observed relaxin-3-positive fibers in the rat medial septum terminating on neurons expressing choline acetyltransferase, parvalbumin, and glutamate decarboxylase ([@B160]); but this "indirect" method is labor intensive and future studies would benefit from the development of an RXFP3 antibody, or transgenic mice which express a reporter gene under the control of the RXFP3 promoter (e.g., [@B46]).

Acute icv infusion of an RXFP3 agonist decreased the time rats spent immobile in the Porsolt forced swim test ([@B177]), which is used to test for putative antidepressant drug action. However, more recently this measure of "depressive-like" behavior has been described as having poor predictive, face, and construct validity ([@B154]), particularly as such changes in behavior are evident in rodents following acute administration of SSRIs, while these drugs require chronic administration over weeks in humans before therapeutic effects are observed. It is also possible that the Porsolt paradigm, which was developed to test drugs that target monoamine systems, may not be optimal for assessing drugs that target neuropeptide receptors. Therefore, it will be important to test the antidepressant potential of acute and chronic delivery of RXFP3 agonists against behavioral measures such as anhedonia and aberrant reward-associated perception, and memory in additional validated rodent models of depression, such as the chronic unpredictable mild stress, chronic social defeat, and chronic methamphetamine withdrawal models ([@B154]; [@B176]) and/or assess effects on brain activity patterns ([@B136]).

Similarly, it will be of interest to assess whether RXFP3 agonists (or antagonists) can improve social behavior in one or more of the rodent models of ASD, such as the commonly used BTBR ([@B189]) and transgenic mouse strains ([@B165]). Determining whether RXFP3 antagonists are protective against the obesity and metabolic syndromes induced by high fat diets in rodents is also a logical and important goal ([@B163]; [@B65]).

These studies would benefit greatly from the development of small molecule RXFP3 agonists and antagonists with a stable *in vivo* half-life that can cross the blood--brain barrier, and hence could be administered peripherally. Such compounds would penetrate the brain more evenly and in a manner more closely resembling the method that would eventually be adopted in humans, rather than preferentially accessing regions near the ventricular system, which occurs following icv infusions. Peripheral delivery methods also circumvent the need for surgical implantation of indwelling guide cannulae in experimental studies. The development of such compounds has not been reported, however, despite initial efforts by some groups (e.g., [@B6]).

In the meantime, further experimental studies are likely to benefit from recently developed and novel methods to manipulate the relaxin-3/RXFP3 system. For example, the RXFP3 agonist "R3/I5" has been successfully delivered chronically into the PVN of rats using an adeno-associated viral construct ([@B63]), which improves upon previous studies which relied on repeated injections ([@B132]) or osmotic minipump infusions of exogenous peptide ([@B74]; [@B201]), which are stressful and invasive techniques that can potentially alter behavior. The development and study of conditional rxfp3 KO mice in which RXFP3 protein could be deleted either globally or within specific brain regions in adult mice would not only help characterize the regional role of endogenous relaxin-3/RXFP3 signaling, but should also prevent the "masking" of phenotypes which may occur due to developmental compensation in life-long relaxin-3 KO mice ([@B192]).

The clustered/restricted distribution of relaxin-3 neurons within the NI readily enables targeting of these neurons with injected viral constructs ([@B38]), which could be used to drive the expression of virally encoded genes of interest under the control of the relaxin-3 promoter ([@B205]). Cell type-specific expression of light-gated ion channels has become a powerful resource for the anatomical and functional deconstruction of neuronal networks and allows the structural dynamics and electrical activity of genetically defined neurons to be manipulated and analyzed on the millisecond timescale ([@B238]; [@B234]; [@B91]). The overall function of relaxin-3 NI neurons could be similarly assessed via targeted expression of channelrhodopsins and related functional measures. Similarly, the expression in NI GABA/relaxin-3 expressing neurons of excitatory and inhibitory "Designer Receptors Exclusively Activated by Designer Drugs" (DREADDs; [@B151]; [@B184]; [@B60]; [@B226]) will allow the effects of acute and chronic activation/inhibition of these neurons on brain circuit activity and behavior to be conveniently studied in freely moving animals. These studies will be important in delineating whether in the NI, it is relaxin-3 or GABA signaling or GABA signaling specifically associated with the relaxin-3-expressing neurons that is primarily linked to effects on brain network activity and changes in behavior (see e.g., GABA/AgRP neurons in the arcuate nucleus in control of feeding ([@B12]; [@B111]).

For effective drug development in the future, the definition and characterization of depression and antidepressant drug treatment effects, currently based heavily on symptomatic criteria, needs to be improved, so that greater emphasis is placed on the underlying dysfunction at the circuit, neuron, and transmitter level (see [@B139]; [@B230]). In this regard, characterizing the potential involvement of novel transmitter systems such as relaxin-3 in the etiology of depression will be of interest. Although relaxin-3 and RXFP3 are genetically highly conserved between rodents and humans, more experiments are needed to demonstrate conserved functions of these signaling networks. The anatomical distribution of relaxin-3 and RXFP3 in non-human primate brain is very similar to that observed in rat and mouse ([@B119],[@B120]); and so "select" studies in non-human primates should be informative ([@B229]). Further studies of any potential involvement of relaxin-3 in the etiology of neurological or psychiatric diseases are also warranted (*c.f.* [@B107]). For example, in addition to comprehensive searches for polymorphisms in the relaxin-3 or RXFP3 genes that might result in altered neurotransmission and affective behavior; once suitably validated assays for human relaxin-3 peptide and/or RXFP3 protein levels are available, studies to determine whether these are altered in patients who suffer from depression and other mental disorders could be completed, as potential markers for dysregulation of relaxin-3/RXFP3 related signaling. Any such findings would, based on prior experience with other peptide-receptor systems such as NPS and PACAP ([@B164]; [@B171]), provide a significant stimulus to this relatively new area of research.

Finally, there are clear signs in the academic literature and emerging from government agencies and Pharma that the field of psychiatric disease research is entering a new era in relation to better understanding and improved drug and environmental-based treatments. This involves an emphasis on analyzing the neural circuitry that causes these brain diseases, rather than a reliance on more "isolated" conventional neurotransmitter and receptor based studies or isolated gene-based studies ([@B139]; [@B1]; [@B85],[@B86]). Thus, newly identified signaling systems like relaxin-3/RXFP3 will need to be studied in the context of regulatory impacts on key neural circuits under physiological and pathological conditions in human (patient-relevant) and industry-validated experimental models, and demonstrate genuine efficacy to restore the required balance of excitatory/inhibitory transmission in one or more diseases.

However, given the relative paucity of new therapeutic drug discoveries in the field over the last several decades using "older style" techniques, this recent realization and redirection in psychiatric disease research in some way removes any disadvantage a "new, little investigated" system such as this might have over other more exhaustively explored systems. Certainly, based on what is known regarding the anatomical distribution of relaxin-3/RXFP3 networks and the prominent effects they can demonstrate on fundamental processes (such as coherent neural firing in the "septohippocampal system" and associated limbic circuits ([@B59]; [@B115]) and effects on circadian activity related circuits ([@B192]; [@B30]), there is reason for optimism regarding its ability to be relevant therapeutically and to attract the attention of major Pharma.

CONCLUSION
==========

The study of neuropeptide-receptor systems is a key area of neuropsychopharmacology research and has revealed the involvement of several peptide systems in mental illnesses, in addition to identifying novel targets for their treatment. Relaxin-3 is a highly conserved neuropeptide in mammalian brain. Relaxin-3 neurons located in the midbrain and pons, innervate a broad range of RXFP3-rich circuits (hypothalamic, septohippocampal, and limbic) to modify stress, arousal, and other modalities that are often dysfunctional in neuropsychiatric diseases. Therefore, further elucidating the full array of relaxin-3/RXFP3 network effects under normal and pathological conditions represents an important and promising research goal, which may eventually help meet the challenges and opportunities for improving the symptomatic treatment of sufferers of conditions such as anxiety and major depression, and the social and cognitive deficits in neurodevelopmental, and degenerative disorders, by restoring the required balance of excitatory/inhibitory transmission within the appropriate neural circuits.
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